Back to Feed
Fintech
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
Prnewswire·
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned...
Original Source
Prnewswire — www.prnewswire.com